ANDA 62402, held by Watson Labs. Nystatin.
As of Nov 14, 2026, ANDA 62402 (Nystatin), held by Watson Labs, was first approved by FDA on Dec 16, 1982, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 16, 1982 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nystatin500,000 UNITS ยท tablet;oral | Nystatin | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
